Previous 10 | Next 10 |
-- Primary study endpoint demonstrates 86 percent response rate for patients receiving co-therapy of KRYSTEXXA and mycophenolate mofetil -- Horizon Therapeutics plc (Nasdaq: HZNP) announced the publication of data from the first randomized controlled clinical trial (RCT) of ...
Happy employees can create effective companies. So when a business makes it onto Fortune magazine's "Best Workplaces" list five years in a row, it suggests that employees are content, and shareholders are likely being handsomely rewarded in the process. Consider Horizon Therapeuti...
-- Data from the pivotal N-MOmentum trial will highlight UPLIZNA long-term safety and efficacy, as well as its impact on pain in NMOSD patients -- -- New survey results demonstrate NMOSD patient attitudes towards diagnosis and treatment -- Horizon Therapeutics plc (N...
Oppenheimer is downgrading shares of Ascendis Pharma (ASND) from outperform to perform and removing its $212 price target.Analyst Leland Gershell says that Street estimates for sales of TransCon hGH (lonapegsomatropin) for pediatric growth hormone deficiency, a BLA for which was submitted las...
The FDA has approved Horizon Therapeutics' (HZNP) prior approval supplement ((PAS)) to previous Biologics Licensing Application ((BLA)) giving Horizon authorization to manufacture more Tepezza drug product resulting in an increased number of vials with each manufacturing slot.The company plan...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved a prior approval supplement (PAS) to the previously approved Biologics Licensing Application (BLA) giving Horizon authorization to manufacture more TEPEZZA drug product ...
- Partnership Includes Robust Science, Technology, Engineering, Arts and Math (STEAM) and Rare Disease Awareness Programming - Horizon Therapeutics (Nasdaq: HZNP) and the Cubs today announced a Legacy Partnership that includes a Cubs STEAM Program, presented by Horizon, whic...
Horizon Therapeutics (HZNP) announces the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (pegloticase injection) concomitantly used with methotrexate to treat people with chronic gout refractory to conventional therapy, al...
-- New Clinical Trial Complements Ongoing Efforts to Evolve the Patient Experience with KRYSTEXXA -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a clinical trial that will evaluate a monthly dosing regimen of 16 mg of KRYSTEXXA (...
Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...